Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
17/06/2024 | 22:33 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MLYS | Mineralys Therapeutics Inc |
17/06/2024 | 22:31 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:MLYS | Mineralys Therapeutics Inc |
14/06/2024 | 14:06 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MLYS | Mineralys Therapeutics Inc |
14/06/2024 | 14:00 | GlobeNewswire Inc. | Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors | NASDAQ:MLYS | Mineralys Therapeutics Inc |
09/05/2024 | 13:10 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:MLYS | Mineralys Therapeutics Inc |
09/05/2024 | 13:00 | GlobeNewswire Inc. | Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:MLYS | Mineralys Therapeutics Inc |
06/05/2024 | 14:00 | GlobeNewswire Inc. | Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference | NASDAQ:MLYS | Mineralys Therapeutics Inc |
02/05/2024 | 14:00 | GlobeNewswire Inc. | Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024 | NASDAQ:MLYS | Mineralys Therapeutics Inc |
21/03/2024 | 12:00 | GlobeNewswire Inc. | Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | NASDAQ:MLYS | Mineralys Therapeutics Inc |
13/03/2024 | 21:05 | GlobeNewswire Inc. | Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024 | NASDAQ:MLYS | Mineralys Therapeutics Inc |
15/02/2024 | 22:20 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:MLYS | Mineralys Therapeutics Inc |
08/02/2024 | 14:00 | GlobeNewswire Inc. | Mineralys Therapeutics Announces $120 Million Private Placement Financing | NASDAQ:MLYS | Mineralys Therapeutics Inc |
29/01/2024 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference | NASDAQ:MLYS | Mineralys Therapeutics Inc |
04/01/2024 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer | NASDAQ:MLYS | Mineralys Therapeutics Inc |
21/12/2023 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension | NASDAQ:MLYS | Mineralys Therapeutics Inc |
11/11/2023 | 17:30 | GlobeNewswire Inc. | Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 | NASDAQ:MLYS | Mineralys Therapeutics Inc |
09/11/2023 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics to Participate in Three Upcoming Conferences | NASDAQ:MLYS | Mineralys Therapeutics Inc |
07/11/2023 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update | NASDAQ:MLYS | Mineralys Therapeutics Inc |
02/11/2023 | 15:00 | GlobeNewswire Inc. | Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting | NASDAQ:MLYS | Mineralys Therapeutics Inc |
31/10/2023 | 21:05 | GlobeNewswire Inc. | Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023 | NASDAQ:MLYS | Mineralys Therapeutics Inc |
13/10/2023 | 22:10 | GlobeNewswire Inc. | Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023 | NASDAQ:MLYS | Mineralys Therapeutics Inc |
19/09/2023 | 22:00 | GlobeNewswire Inc. | Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy | NASDAQ:MLYS | Mineralys Therapeutics Inc |
14/09/2023 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas | NASDAQ:MLYS | Mineralys Therapeutics Inc |
11/09/2023 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023 | NASDAQ:MLYS | Mineralys Therapeutics Inc |
10/09/2023 | 13:47 | GlobeNewswire Inc. | Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension | NASDAQ:MLYS | Mineralys Therapeutics Inc |
10/09/2023 | 13:45 | GlobeNewswire Inc. | Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions | NASDAQ:MLYS | Mineralys Therapeutics Inc |
05/09/2023 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions | NASDAQ:MLYS | Mineralys Therapeutics Inc |
29/08/2023 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023 | NASDAQ:MLYS | Mineralys Therapeutics Inc |
07/08/2023 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update | NASDAQ:MLYS | Mineralys Therapeutics Inc |
31/07/2023 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023 | NASDAQ:MLYS | Mineralys Therapeutics Inc |